Sareum (LON:SAR) Trading 27.6% Higher – Here’s What Happened

Sareum Holdings plc (LON:SAR) shares rose 27.6% during trading on Tuesday . The stock traded as high as GBX 38 and last traded at GBX 37. Approximately 2,280,295 shares traded hands during mid-day trading, an increase of 849% from the average daily volume of 240,317 shares. The stock had previously closed at GBX 29.

Sareum Stock Performance

The business’s 50 day moving average is GBX 23.44 and its two-hundred day moving average is GBX 20.22. The firm has a market capitalization of £51.27 million, a PE ratio of -9.49 and a beta of -1.08.

Sareum Company Profile

Sareum is a specialist drug development company delivering targeted small molecule therapeutics to improve the treatment of cancer and autoimmune diseases. The Company aims to generate value through licensing its candidates to international pharmaceutical and biotechnology companies at the preclinical or early clinical trials stage.
Sareum is advancing internal programmes focused on distinct dual tyrosine kinase 2 (TYK2) / Janus kinase 1 (JAK1) inhibitors through preclinical development as therapies for autoimmune diseases, including the ‘cytokine storm’ immune system overreaction to Covid-19 and other viral infections, (SDC-1801) and cancer immunotherapy (SDC-1802).
Sareum also has an economic interest in SRA737, a clinical-stage oral, selective Checkpoint kinase 1 (Chk1) inhibitor that targets cancer cell replication and DNA damage repair mechanisms.